Research programme: FGFR4 inhibitors - Tyra Biosciences
Alternative Names: FGFR4 - Tyra Biosciences; FGFR4 programLatest Information Update: 28 Jan 2026
At a glance
- Originator Tyra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Liver cancer; Solid tumours
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Liver-cancer in USA
- 28 Jan 2026 No recent reports of development identified for research development in Solid-tumours in USA
- 15 Mar 2022 FGFR4 inhibitors - Tyra Biosciences is available for licensing as of 31 Dec 2021.